Understanding COVID-19 Vaccine Immunity in Tissue and Blood
NCT ID: NCT05682625
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2024-10-31
2029-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection
NCT04362865
Immune Response to the COVID-19 Vaccine
NCT04936997
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
NCT06089967
Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects
NCT04408950
Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans
NCT04565067
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants
Adults who are receiving a COVID-19 vaccine
No intervention
No intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with contraindications for lymph node biopsy
* Active cancer
* Current use of immunosuppression drugs
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
R. Sharon Chinthrajah
Associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
R. Sharon Chinthrajah, MD
Role: PRINCIPAL_INVESTIGATOR
Stanford University, Sean N. Parker Center for Allergy and Asthma Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University
Palo Alto, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-67705
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.